Cipla Gulf expands partnership with Alvotech for commercialization of biosimilars in Australia and New Zealand
Cipla Limited announced that it's subsidiary, Cipla Gulf FZ LCC ("Cipla Gulf')is expanding its partnership with Alvotech for the marketing and supply of four biosimilar medicines in Australia and New Zealand.
As part of the strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of the biologic medication brands, Aflibercept (Eylea®️), Ustekimumab (Stelara), Denosumab (Prolia, Xgeva®️) and Golimumab (Simponi®️). These are top products covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology (eg. Aflibercept is indicated for nAMD and other serious eye diseases).
The products are developed and manufactured by Alvotech and will be distributed by Cipla Gulf via Australia and New Zealand supply networks. These innovative products listed US$700 Mn in aggregate 2020 earnings in Australia.
Cipla Gulf had entered into a similar arrangement with Alvotech in July 2019 for the commercialization of AVT02, an adalimumab biosimilar, in select emerging markets.
Commenting on the partnership, Nishant Saxena, CEO, International Business (Europe & Emerging Markets), Cipla, said “Ensuring access to critical medicines is core to our purpose of ‘Caring for Life’ and this partnership is a step in that direction. We believe Alvotech’s products will enhance our biosimilars pipeline and allow us to establish a pantherapy presence in the specialties segment, improving our footprint in this strategic Australia market.”
Anil Okay, Alvotech’s Chief Commercial Officer said: “We are delighted to be taking this strategic step with Cipla. The combination of Alvotech’s development and manufacturing expertise and Cipla’s commercial capabilities will be central in expanding patient access in the region, to high-quality biosimilars.”